Fresenius Kabi Oncology Ltd.

BSE: 532545 | NSE: FKONCO | Series: NA | ISIN: INE575G01010 | SECTOR: PharmaceuticalsPharmaceuticals

Success

Alert

Please select a Day.

Info

Open trading A/c Open trading A/c

Fresenius Kabi Fresenius Kabi Oncology Ltd. | BSE 132.45 0.00 (0.00%) | NSE 1035.00 902.50 (681.13%) | Trade | Add

BSE Live

Jan 02, 15:50

132.45 0.00 (0.00%)

Volume

No Data Available

Prev. Close

132.45
Open Price

132.00

Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
132.45 (20430)

Fresenius Kabi Oncology is not traded on BSE in the last 30 days

NSE Live

Oct 13, 12:27

1035.00 902.50 (681.13%)

Volume

No Data Available

Prev. Close

132.50
Open Price

1030.60

Bid Price (Qty.)
1033.80 (729)
Offer Price (Qty.)
1035.87 (652)

Fresenius Kabi Oncology is not traded on NSE in the last 30 days

Company History - Fresenius Kabi Oncology

2003
 
 -Sets up a new six member board to give strategic inputs and
 direction to the company
 
 2004
 
 -Dabur Pharma enters NSE, BSE
 
 2006
 
 -Dabur Pharma Limited has informed that Mr. V. V. Dharkar has joined
 the Company as Chief Financial Officer w.e.f December 01, 2006.
 
 2007
 
 -Dabur Pharma on January 4,2007 unveiled new nano technology based
 chemotherapy agent, Nanoxel, in the country.
 
 -Dabur Pharma has informed that Mr. Shailendra Tandon has joined the
 Company as Chief Financial Officer w.e.f. June 26, 2007.
 
 2009
 
 - Company name has been changed from Dabur Pharma Ltd to Fresenius
 Kabi Oncology Ltd.
 
 
 2010
 
 - Opening of newly developed premier Innovation & Development Center
 and Corporate Office at Gurgaon.
 
 - Fresenius Kabi Oncology Ltd Enters Into a Licensing And Settlement
 Agreement with Sanofi-Aventis.
 
 2011
 
 - Dissolution of Wholly owned Subsidiary Dabur Pharma (Thailand) Co.
 Ltd.

Fresenius Kabi Oncology Ltd.

Quick links

News

Corporate Action

Information

Financials

Annual Report

Peer Comparison

Related Searches